Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

Verena Pfister, Fernanda de Morais Marques, Vinicius Campos de Molla, Flavia Parra, Mihoko Yamamoto, Rodrigo Santucci, Milton A. F. Aranha, Valeria Buccheri, Glaciano Ribeiro, Vera Figueiredo, Nelson Hamerschlak, Abel Costa Neto, Jayr Schmidt Filho, Talita Silveira, Adriana Scheliga, Matheus Vescovi Goncalves, Leila Perobelli, Carlos Chiattone, Celso Arrais-Rodrigues

Blood (2024) 144 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2024-210706

Published: 2024

Journal Articles

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Blood (2023) 142 (Supplement 1): 6200.

https://doi.org/10.1182/blood-2023-173318

Published: 2023

Journal Articles

Contribution of Genetic Screening to the Diagnosis of Patients with Bone Marrow Failure and Short Telomeres

Thaís B. Barbosa Rodrigues, Thales D.M. Pereira, Valeria Buccheri, Flavia Donaires, Andre L.P. Santos, Denise C. Paranaguá-Vezozzo, Vanderson Rocha, Rodrigo T. Calado, Elvira Deolinda Rodrigues Pereira Velloso

Blood (2023) 142 (Supplement 1): 5658.

https://doi.org/10.1182/blood-2023-185133

Published: 2023

Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Blood (2023) 142 (Supplement 1): 6534.

https://doi.org/10.1182/blood-2023-190590

Published: 2023

Journal Articles

Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma

Fernanda Maria Maria Santos, Jose Flavio Gomes Marin, Marcos Santos Lima, Wellington F Silva, Rodrigo D Velasques, Ana Carolina Arrais Maia, Marcelo Junqueira Atanazio, Lucas Bassolli de Oliveira Alves, Frederico Rafael Moreira, Carlos Alberto Buchpiguel, Valeria Buccheri, Vanderson Rocha

Blood (2022) 140 (Supplement 1): 6586–6587.

https://doi.org/10.1182/blood-2022-167663

Published: 2022

Journal Articles

Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia

Jean Carlos Lipreri Da Silva, Felipe Saldanha-Araujo, Raphael Costa Bandeira de Melo, Hugo Passos Vicari, Amandda Évelin Silva De Carvalho, Eduardo M Rego, Valeria Buccheri, João Agostinho Machado-Neto

Blood (2022) 140 (Supplement 1): 12359–12360.

https://doi.org/10.1182/blood-2022-160267

Published: 2022

Journal Articles

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Marcelo Pitombeira de Lacerda, Fernanda de Morais Marques, Verena Pfister, Flavia de Carvalho Parra, Vinicius Campos de Molla, Valeria Buccheri, Rafael Dezen Gaiolla, Laura Maria Fogliatto, Rodrigo Santucci, Marcelo Bellesso, Sérgio Costa Fortier, Talita M.B. Silveira, Glaciano Ribeiro, Nelson Hamerschlak, Mihoko Yamamoto, Matheus Vescovi Goncalves, Carlos S. Chiattone, Celso Arrais-Rodrigues

Blood (2022) 140 (Supplement 1): 7041–7042.

https://doi.org/10.1182/blood-2022-170872

Published: 2022

Journal Articles

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142520

Published: 2020

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Guilherme Brasil Duffles Amarante, MD, Valeria Buccheri, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142810

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Elvira DRP Velloso, MD PhD, Maria Gabriella Cordeiro, Danielle Lucon, PhD, Renata Kishimoto, Aline Medeiros Leal, PhD, Ana Carolina Arrais Maia, MD, Valeria Buccheri, MD PhD, Israel Bendit, MD PhD, Wellington Fernandes Silva, Jr., MD, Cristovao Mangueira, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 5288.

https://doi.org/10.1182/blood-2018-99-115426

Published: 2018

Journal Articles

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

Carlos Sérgio Chiattone, MD, Nelson Hamerschlak, MD PhD, Laura Fogliatto, Phillip Scheinberg, MD, Ricardo Bigni, MD MPH, Celso Rodrigues, MD PhD, Bernardo Garicochea, Alex Pimenta, Tiago Oliveira Boechat, MD, Juliane Musacchio, MD PhD, Jaisson Bortolini, MD, Iara Zapparoli Goncalves, MD, Garles Miller Matias Vieira, Valeria Buccheri, MD PhD, Telma Santos, Mariana Grings, Lori Parisi, Paula Barreyro, MD

Blood (2018) 132 (Supplement 1): 5554.

https://doi.org/10.1182/blood-2018-99-116720

Published: 2018

Journal Articles

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

Talita Silveira Da Rocha, MD, Sergio Costa Fortier, MD, Nelson Siqueira de Castro, MD, Marcia T Delamain, MD, José Salvador Oliveira, PhD, Guilherme Perini, MD, Valeria Buccheri, PhD, Rafael Dezen Gaiolla, MD, Laura Fogliato, PhD, Andressa Laranja, Maeva Pinto, MD, Carlos Chiattone, MD PhD

Blood (2015) 126 (23): 5107.

https://doi.org/10.1182/blood.V126.23.5107.5107

Published: 2015

Journal Articles

Non-Inferior Pharmacokinetics with Comparable Safety and Response Rates for Subcutaneous (SC), Compared with Intravenous (IV), Rituximab in Combination with Fludarabine and Cyclophosphamide (FC) in Patients (Pts) with Untreated Chronic Lymphocytic Leukemia (CLL): Part 2 of the Phase Ib SAWYER Study (BO25341)

Sarit Assouline, MD MSc, Valeria Buccheri, MD PhD, Alain Delmer, MD, Gianluca Gaidano, MD PhD, Michael Brewster, BSc, Olivier Catalani, Sai Li, MD PhD, Christine McIntyre, PhD, Pakeeza Sayyed, PhD, Xavier C Badoux, MBBS

Blood (2014) 124 (21): 1995.

https://doi.org/10.1182/blood.V124.21.1995.1995

Published: 2014

Journal Articles

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Sarit Assouline, Valeria Buccheri, MD; PhD., Alain Delmer, MD, Gottfried Doelken, MD, Gianluca Gaidano, MD, PhD, Christine McIntyre, Mike Brewster, Florence Hourcade-Potelleret, PhD, Pakeeza Sayyed, Xavier Badoux, MB BS FRACP FRCPA

Blood (2012) 120 (21): 1637.

https://doi.org/10.1182/blood.V120.21.1637.1637

Published: 2012

Journal Articles

Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution

Camila C.G. Linardi, MD; PhD., Luis Fernando Pracchia, MD., Rodrigo Dolphini Velasques, MD., Claudia Bitti Barroso, MD, Valeria Buccheri, MD; PhD.

Blood (2011) 118 (21): 3153.

https://doi.org/10.1182/blood.V118.21.3153.3153

Published: 2011

NARROW

Real-World Analysis of Patients with CLL Treated with Ibrutinib: A Retrospective Analysis of the Brazilian Registry of CLL

External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry

Contribution of Genetic Screening to the Diagnosis of Patients with Bone Marrow Failure and Short Telomeres

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma

Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Open-Label Early-Access Programs (EAPs) for Ibrutinib in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia (CLL) or Mantle-Cell Lymphoma (MCL)

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

Hodgkin Lymphoma: 20 Years Experience From a Single Brazilian Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only